A Safety and Efficacy Study of MSI-1256F (Squalamine Lactate) To Treat "Wet" Age-Related Macular Degeneration

Stopped early · Phase 2

Conditions studied: Macular Degeneration

In brief

Age-Related Macular Degeneration (AMD) is a degenerative eye disease of the retina that causes a progressive loss of central vision. AMD is the leading cause of legal blindness among adults age 50 or older in the Western world. AMD presents in two different types - "dry" and the more severe "wet" form. Wet AMD is caused by the growth of abnormal blood vessels in the macula. Squalamine lactate is an investigational drug that may prevent the growth of these abnormal blood vessels. This study will test the safety and efficacy of Squalamine in the treatment of AMD.

Key facts

Study ID

NCT00089830

Run by

Genaera Corporation

People needed

120

Starts

2004-08-01

Expected to finish

2007-05-01

Last updated by the study team

2007-11-28

Who can join

Age: 50 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Patients with a diagnosis of "wet" age-related macular degeneration

You may not qualify if…

• Prior treatment of "wet" age-related macular degeneration in the affected eye in the past 3 months

Where it is running

• Genaera Corporation — Plymouth Meeting, Pennsylvania, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.